Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 4 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Recs

0
Player Avatar R1000 (< 20) Submitted: 7/11/2012 10:13:12 PM : Outperform Start Price: $5.79 EXEL Score: -28.55

Because I was an early investor in DNDN and didn't sell in time I became curious about Exelixis, a firm competitor. I am buying in at a price below it's 52 week high. It has a lot of events coming up and I think the data revealed will move the price.

Featured Broker Partners


Advertisement